CA3209454A1 - Antibodies that bind cd123 and gamma-delta t cell receptors - Google Patents

Antibodies that bind cd123 and gamma-delta t cell receptors Download PDF

Info

Publication number
CA3209454A1
CA3209454A1 CA3209454A CA3209454A CA3209454A1 CA 3209454 A1 CA3209454 A1 CA 3209454A1 CA 3209454 A CA3209454 A CA 3209454A CA 3209454 A CA3209454 A CA 3209454A CA 3209454 A1 CA3209454 A1 CA 3209454A1
Authority
CA
Canada
Prior art keywords
seq
set forth
sequence set
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3209454A
Other languages
English (en)
French (fr)
Inventor
Robertus Cornelis ROOVERS
Johannes Jelle VAN DER VLIET
David Lutje Hulsik
Paul Willem Henri Ida PARREN
Jurjen Matthijs RUBEN
Charlotte Merette MOUSSET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lava Therapeutics NV
Original Assignee
Lava Therapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics NV filed Critical Lava Therapeutics NV
Publication of CA3209454A1 publication Critical patent/CA3209454A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3209454A 2021-02-26 2022-02-28 Antibodies that bind cd123 and gamma-delta t cell receptors Pending CA3209454A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21159698.6 2021-02-26
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US63/166,339 2021-03-26
US202163274709P 2021-11-02 2021-11-02
US63/274,709 2021-11-02
EP21211114.0 2021-11-29
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (1)

Publication Number Publication Date
CA3209454A1 true CA3209454A1 (en) 2022-09-01

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3209454A Pending CA3209454A1 (en) 2021-02-26 2022-02-28 Antibodies that bind cd123 and gamma-delta t cell receptors

Country Status (9)

Country Link
US (1) US20240141071A1 (https=)
EP (1) EP4298125A1 (https=)
JP (1) JP2024507937A (https=)
KR (1) KR20230169950A (https=)
AU (1) AU2022225091A1 (https=)
BR (1) BR112023017099A2 (https=)
CA (1) CA3209454A1 (https=)
MX (1) MX2023009950A (https=)
WO (1) WO2022180271A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP3129404B1 (en) * 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
BR112020020604A2 (pt) * 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Ｃｄ１２３結合性ポリペプチド及びその使用
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY

Also Published As

Publication number Publication date
KR20230169950A (ko) 2023-12-18
BR112023017099A2 (pt) 2023-11-21
MX2023009950A (es) 2023-11-10
EP4298125A1 (en) 2024-01-03
JP2024507937A (ja) 2024-02-21
US20240141071A1 (en) 2024-05-02
WO2022180271A1 (en) 2022-09-01
AU2022225091A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
AU2022223152B2 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
CA3164979A1 (en) New polypeptide complex
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
AU2019337394A1 (en) Improved anti-FLT3 antigen binding proteins
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
CA3111462C (en) Improved anti-flt3 antigen binding proteins
WO2026002175A1 (zh) 靶向ilt7和cd89的髓细胞衔接子抗体及其用途
TW202607041A (zh) 靶向ｉｌｔ７和ｃｄ８９的髓細胞銜接子抗體及其用途
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
CN121270705A (zh) 抗cMET抗体
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体

Legal Events

Date Code Title Description
U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260220

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260226

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260310